CereVasc Revenue and Competitors

Claim your profile

Auburndale, MA USA

Location

$44M

Total Funding

Estimated Revenue & Valuation

  • CereVasc's estimated annual revenue is currently $2.1M per year.(i)
  • CereVasc's estimated revenue per employee is $125,500
  • CereVasc's total funding is $44M.

Employee Data

  • CereVasc has 17 Employees.(i)
  • CereVasc grew their employee count by 31% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.5M383%N/AN/A
#2
$8.3M3314%N/AN/A
#3
$4M1633%N/AN/A
#4
$4.3M17-6%N/AN/A
#5
$5630M69534%$450MN/A
#6
$4M1633%N/AN/A
#7
$7.2M5727%$29.6MN/A
#8
$14.1M560%N/AN/A
#9
$2.1M1731%$44MN/A
#10
$40.9M163-23%N/AN/A
Add Company

CereVasc, Inc. is developing the eShuntâ„¢ System for the treatment of patients with communicating hydrocephalus, one of the most common neurological conditions affecting both children and adults.

keywords:N/A

$44M

Total Funding

17

Number of Employees

$2.1M

Revenue (est)

31%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CereVasc News

2022-04-19 - First patient treated in CereVasc® clinical trial of eShunt ...

Clinical trial underway in Argentina to study minimally invasive treatment for NPH. BOSTON, April 25, 2022 /PRNewswire/ -- CereVasc, Inc.,...

2020-06-10 - CereVasc Closes $43.9M Series A Financing

CereVasc, Inc., a Boston, MA-based company focused on improving the treatment of patients with hydrocephalus, closed an expanded Series A financing that raised a total of $43.9m. The round was led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC. Led by Dan Levangie, Chair ...

2020-06-09 - CereVasc Closes $43.9 Million Series A

BOSTON--(BUSINESS WIRE)--CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC. The ...

2020-06-09 - CereVasc Announces Closing of $43.9 Million Series A Financing

– Proceeds to fund clinical trials of the eShunt™ System for treatment of hydrocephalus – – Series A financing led by the Perceptive Xontogeny Venture Fund – BOSTON–(BUSINESS WIRE)–June 9, 2020– CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, annou ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5M250%N/A
#2
$3.4M353%N/A
#3
$4.4M462%N/A
#4
$5.8M48-13%N/A
#5
$8.6M497%N/A